Found: 77
Select item for more details and to access through your institution.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 4, p. 382, doi. 10.1111/hepr.13991
- By:
- Publication type:
- Article
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 1031, doi. 10.1111/hepr.13934
- By:
- Publication type:
- Article
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
- Published in:
- Hepatology Research, 2023, v. 53, n. 8, p. 737, doi. 10.1111/hepr.13905
- By:
- Publication type:
- Article
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice.
- Published in:
- Hepatology Research, 2022, v. 52, n. 9, p. 773, doi. 10.1111/hepr.13797
- By:
- Publication type:
- Article
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 462, doi. 10.1111/hepr.13748
- By:
- Publication type:
- Article
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 308, doi. 10.1111/hepr.13734
- By:
- Publication type:
- Article
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
- Published in:
- Hepatology Research, 2021, v. 51, n. 8, p. 880, doi. 10.1111/hepr.13644
- By:
- Publication type:
- Article
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2021, v. 51, n. 6, p. 694, doi. 10.1111/hepr.13633
- By:
- Publication type:
- Article
Abnormal fucosylation of alpha‐fetoprotein in patients with nonalcoholic steatohepatitis.
- Published in:
- Hepatology Research, 2021, v. 51, n. 5, p. 548, doi. 10.1111/hepr.13626
- By:
- Publication type:
- Article
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
- Published in:
- Hepatology Research, 2021, v. 51, n. 2, p. 201, doi. 10.1111/hepr.13592
- By:
- Publication type:
- Article
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 6, p. 565, doi. 10.1159/000530078
- By:
- Publication type:
- Article
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
- By:
- Publication type:
- Article
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 3, p. 181, doi. 10.1159/000514174
- By:
- Publication type:
- Article
Reply to the Letter "Comment on Regarding Manuscript 'Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies'".
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
- By:
- Publication type:
- Article
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 6, p. 734, doi. 10.1159/000508971
- By:
- Publication type:
- Article
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.
- Published in:
- Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
- By:
- Publication type:
- Article
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
- Published in:
- Liver International, 2024, v. 44, n. 7, p. 1736, doi. 10.1111/liv.15964
- By:
- Publication type:
- Article
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
- Published in:
- Liver International, 2024, v. 44, n. 6, p. 1456, doi. 10.1111/liv.15907
- By:
- Publication type:
- Article
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma.
- Published in:
- Liver International, 2024, v. 44, n. 1, p. 113, doi. 10.1111/liv.15753
- By:
- Publication type:
- Article
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Liver International, 2020, v. 40, n. 4, p. 968, doi. 10.1111/liv.14405
- By:
- Publication type:
- Article
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching.
- Published in:
- Hepatology Research, 2020, v. 50, n. 1, p. 75, doi. 10.1111/hepr.13427
- By:
- Publication type:
- Article
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.
- Published in:
- Hepatology Research, 2019, v. 49, n. 1, p. 111, doi. 10.1111/hepr.13243
- By:
- Publication type:
- Article
A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin–bilirubin grade.
- Published in:
- Hepatology Research, 2018, v. 48, n. 3, p. E61, doi. 10.1111/hepr.12927
- By:
- Publication type:
- Article
Modified radiofrequency ablation for the treatment of hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2016, v. 46, n. 11, p. 1158, doi. 10.1111/hepr.12683
- By:
- Publication type:
- Article
Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients.
- Published in:
- Hepatology Research, 2012, v. 42, n. 11, p. 1058, doi. 10.1111/j.1872-034X.2012.01025.x
- By:
- Publication type:
- Article
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
- By:
- Publication type:
- Article
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
- By:
- Publication type:
- Article
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
- By:
- Publication type:
- Article
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
- By:
- Publication type:
- Article
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
- Published in:
- Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292
- By:
- Publication type:
- Article
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
- Published in:
- Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
- By:
- Publication type:
- Article
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
- By:
- Publication type:
- Article
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
- By:
- Publication type:
- Article
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
- By:
- Publication type:
- Article
Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.
- Published in:
- Oncology, 2016, v. 91, n. 3, p. 153, doi. 10.1159/000447061
- By:
- Publication type:
- Article
Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma.
- Published in:
- Oncology, 2015, v. 89, p. 19, doi. 10.1159/000440627
- By:
- Publication type:
- Article
Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma with Decompensated Cirrhosis.
- Published in:
- Oncology, 2011, v. 81, n. 1, p. 39, doi. 10.1159/000331411
- By:
- Publication type:
- Article
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
- Published in:
- Cancer Reports, 2024, v. 7, n. 4, p. 1, doi. 10.1002/cnr2.2042
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
- Published in:
- Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1464
- By:
- Publication type:
- Article
Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
- Published in:
- Journal of Viral Hepatitis, 2022, v. 29, n. 10, p. 919, doi. 10.1111/jvh.13728
- By:
- Publication type:
- Article
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
- By:
- Publication type:
- Article
Letter: rising incidence and poor survival in patients with non‐viral HCC – better HCC surveillance and treatment for alcohol‐associated and non‐alcohol fatty liver diseases are needed. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 3, p. 363, doi. 10.1111/apt.17361
- By:
- Publication type:
- Article
Editorial: non‐viral hepatocellular carcinoma surveillance—an increasingly severe public health issue. Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Improved survival of viral hepatocellular carcinoma but not non‐viral hepatocellular carcinoma from 2000 to 2020: A multi‐centre cohort study of 6007 patients from high‐volume academic centres in Japan.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 4, p. 694, doi. 10.1111/apt.17088
- By:
- Publication type:
- Article
A case of generalized morphea complicated by autoimmune hepatitis.
- Published in:
- Our Dermatology Online / Nasza Dermatologia Online, 2021, v. 12, n. 1, p. 99, doi. 10.7241/ourd.20211.31
- By:
- Publication type:
- Article
Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.
- Published in:
- Liver Cancer International, 2023, v. 4, n. 3, p. 101, doi. 10.1002/lci2.74
- By:
- Publication type:
- Article
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 8, p. 3719, doi. 10.1002/cam4.2241
- By:
- Publication type:
- Article
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 1, p. 137, doi. 10.1002/cam4.1909
- By:
- Publication type:
- Article
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 1, p. 269, doi. 10.1007/s40121-020-00364-9
- By:
- Publication type:
- Article